HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT02783430

Ketamine Added to Milnacipran for Depression in Palliative Care

About this titleRead the official source — NCT02783430
Medication studyAges 18+France
The study in practice

Understand this study

Who was this study for?

Listed age limits: from 18 years.

Listed locations
Amiens and 8 more locationsSee all locations and recruitment
Study phase
Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: September 8, 2016
Recruitment status
Completed
Enrollment listed in the registry
42
Sponsor
University Hospital, Lille
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Locations
France
Age range
Over 18 Years
Official registry ID
NCT02783430
Official title
Show the full official title

Evaluation of the Initial Prescription of Ketamine and Milnacipran Forin Depression in Patients With a Progressive Disease

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Amiens · Calais · Lille

5 more locations
  • Lomme
  • Roubaix
  • Senlis
  • Tourcoing
  • Valenciennes
FAQ

Questions about this study

Who is behind this study?

The study sponsor is University Hospital, Lille, a hospital or academic medical center.

Did this study involve medication?

Yes. The study involved medication, including ketamine, Milnacipran and Placebo.

Who was this study for?

Listed age limits: from 18 years.

Want to explore more studies?

Explore studies